Do analysts prefer DXRX or IDHC?

Diaceutics presently has a consensus target price of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Integrated Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Integrated Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to DXRX or IDHC?

In the previous week, Diaceutics and Diaceutics both had 1 articles in the media. Diaceutics' average media sentiment score of 0.92 beat Integrated Diagnostics' score of 0.00 indicating that Diaceutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Diaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integrated Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ABDX or DXRX?

Diaceutics has a consensus price target of GBX 215, indicating a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Abingdon Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abingdon Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate GDR or DXRX?

Diaceutics has a consensus target price of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than genedrive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score genedrive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, GDR or DXRX?

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio genedrive £929K 21.59 -£21.22M -£0.79 N/A Diaceutics £38.44M 3.60 -£2.84M £0.11 1,481.82

Is GDR or DXRX more profitable?

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets genedrive -500.75% -1,044.57% -74.09% Diaceutics 0.25% 0.25% -6.06%

Does the media prefer GDR or DXRX?

In the previous week, genedrive had 1 more articles in the media than Diaceutics. MarketBeat recorded 2 mentions for genedrive and 1 mentions for Diaceutics. Diaceutics' average media sentiment score of 0.92 beat genedrive's score of 0.22 indicating that Diaceutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment genedrive 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Diaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate DXRX or YGEN?

Diaceutics presently has a consensus target price of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Diaceutics is more favorable than Yourgene Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Yourgene Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate DXRX or AGL?

Diaceutics presently has a consensus price target of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher probable upside, research analysts clearly believe Diaceutics is more favorable than ANGLE. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 ANGLE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, DXRX or AGL?

Diaceutics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Diaceutics £38.44M 3.60 -£2.84M £0.11 1,481.82 ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A

Is DXRX or AGL more profitable?

Diaceutics has a net margin of 0.25% compared to ANGLE's net margin of -1,444.04%. Diaceutics' return on equity of 0.25% beat ANGLE's return on equity. Company Net Margins Return on Equity Return on Assets Diaceutics 0.25% 0.25% -6.06% ANGLE -1,444.04% -191.36% -29.89%

Does the media refer more to DXRX or AGL?

In the previous week, Diaceutics and Diaceutics both had 1 articles in the media. Diaceutics' average media sentiment score of 0.92 beat ANGLE's score of 0.00 indicating that Diaceutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Diaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANGLE 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Diaceutics (DXRX) Competitors

GBX 163 +3.00 (+1.88%)

As of 04:14 AM Eastern

Compare

DXRX vs. IDHC, ABDX, GDR, YGEN, and AGL

Should you buy Diaceutics stock or one of its competitors? Diaceutics's main competitors and comparable companies include Integrated Diagnostics (IDHC), Abingdon Health (ABDX), genedrive (GDR), Yourgene Health (YGEN), and ANGLE (AGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Diaceutics compare to Integrated Diagnostics?

Diaceutics (LON:DXRX) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Integrated Diagnostics has higher revenue and earnings than Diaceutics. Integrated Diagnostics is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.60	-£2.84M	£0.11	1,481.82
Integrated Diagnostics	£9.17B	0.00	£4.01T	£250.03	0.00

Integrated Diagnostics has a net margin of 16.49% compared to Diaceutics' net margin of 0.25%. Integrated Diagnostics' return on equity of 39.61% beat Diaceutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
Integrated Diagnostics	16.49%	39.61%	9.69%

Diaceutics presently has a consensus target price of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Integrated Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Integrated Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

26.9% of Diaceutics shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 26.3% of Diaceutics shares are held by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Diaceutics has a beta of 0.884, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, suggesting that its stock price is 57% less volatile than the broader market.

In the previous week, Diaceutics and Diaceutics both had 1 articles in the media. Diaceutics' average media sentiment score of 0.92 beat Integrated Diagnostics' score of 0.00 indicating that Diaceutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Diaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integrated Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Diaceutics beats Integrated Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Diaceutics compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Diaceutics has a consensus price target of GBX 215, indicating a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Abingdon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abingdon Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Diaceutics had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Abingdon Health. Diaceutics' average media sentiment score of 0.92 beat Abingdon Health's score of 0.00 indicating that Diaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abingdon Health	Neutral
Diaceutics	Positive

Diaceutics has a net margin of 0.25% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of 0.25% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abingdon Health	-33.88%	-55.91%	-17.93%
Diaceutics	0.25%	0.25%	-6.06%

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 26.9% of Diaceutics shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by insiders. Comparatively, 26.3% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Abingdon Health has higher earnings, but lower revenue than Diaceutics. Abingdon Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abingdon Health	£9.57M	2.82	-£796.37K	-£0.81	N/A
Diaceutics	£38.44M	3.60	-£2.84M	£0.11	1,481.82

Abingdon Health has a beta of 0.132, suggesting that its share price is 87% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.884, suggesting that its share price is 12% less volatile than the broader market.

Summary

Diaceutics beats Abingdon Health on 15 of the 16 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

genedrive (LON:GDR) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
genedrive	-500.75%	-1,044.57%	-74.09%
Diaceutics	0.25%	0.25%	-6.06%

Diaceutics has a consensus target price of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than genedrive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
genedrive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

0.1% of genedrive shares are held by institutional investors. Comparatively, 26.9% of Diaceutics shares are held by institutional investors. 28.1% of genedrive shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
genedrive	£929K	21.59	-£21.22M	-£0.79	N/A
Diaceutics	£38.44M	3.60	-£2.84M	£0.11	1,481.82

In the previous week, genedrive had 1 more articles in the media than Diaceutics. MarketBeat recorded 2 mentions for genedrive and 1 mentions for Diaceutics. Diaceutics' average media sentiment score of 0.92 beat genedrive's score of 0.22 indicating that Diaceutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
genedrive	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Diaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

genedrive has a beta of 0.968, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.884, meaning that its stock price is 12% less volatile than the broader market.

Summary

Diaceutics beats genedrive on 12 of the 16 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Diaceutics (LON:DXRX) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Diaceutics has higher revenue and earnings than Yourgene Health. Yourgene Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.60	-£2.84M	£0.11	1,481.82
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A

26.9% of Diaceutics shares are owned by institutional investors. Comparatively, 23.3% of Yourgene Health shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by insiders. Comparatively, 64.4% of Yourgene Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Diaceutics presently has a consensus target price of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Diaceutics is more favorable than Yourgene Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Yourgene Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Diaceutics had 1 more articles in the media than Yourgene Health. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Yourgene Health. Diaceutics' average media sentiment score of 0.92 beat Yourgene Health's score of 0.00 indicating that Diaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
Diaceutics	Positive
Yourgene Health	Neutral

Diaceutics has a net margin of 0.25% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of 0.25% beat Yourgene Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
Yourgene Health	-27.55%	-27.06%	-6.71%

Diaceutics has a beta of 0.884, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Summary

Diaceutics beats Yourgene Health on 14 of the 15 factors compared between the two stocks.

How does Diaceutics compare to ANGLE?

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Diaceutics has a net margin of 0.25% compared to ANGLE's net margin of -1,444.04%. Diaceutics' return on equity of 0.25% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
ANGLE	-1,444.04%	-191.36%	-29.89%

Diaceutics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.60	-£2.84M	£0.11	1,481.82
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A

Diaceutics has a beta of 0.884, indicating that its stock price is 12% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Diaceutics presently has a consensus price target of GBX 215, suggesting a potential upside of 31.90%. Given Diaceutics' stronger consensus rating and higher probable upside, research analysts clearly believe Diaceutics is more favorable than ANGLE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ANGLE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

26.9% of Diaceutics shares are owned by institutional investors. Comparatively, 17.5% of ANGLE shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by company insiders. Comparatively, 2.7% of ANGLE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Diaceutics and Diaceutics both had 1 articles in the media. Diaceutics' average media sentiment score of 0.92 beat ANGLE's score of 0.00 indicating that Diaceutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Diaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANGLE	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Diaceutics beats ANGLE on 15 of the 15 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXRX vs. The Competition

Export

Metric	Diaceutics	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£138.32M	£9.85B	£7.21B	£2.87B
Dividend Yield	N/A	1.47%	2.57%	6.26%
P/E Ratio	1,481.82	68.77	272.90	366.51
Price / Sales	3.60	107.10	713.90	90,155.03
Price / Cash	3.12	26.23	77.71	27.89
Price / Book	3.55	5.43	10.46	6.42
Net Income	-£2.84M	£56.67B	£3.49B	£5.89B
7 Day Performance	5.16%	1.06%	-0.75%	-0.26%
1 Month Performance	14.52%	1.04%	-0.38%	-0.54%
1 Year Performance	10.14%	25.45%	18.93%	20.16%

Diaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXRX Diaceutics	2.2072 of 5 stars	GBX 163 +1.9%	GBX 215 +31.9%	+10.3%	£138.32M	£38.44M	1,481.82	151
IDHC Integrated Diagnostics	N/A	GBX 0.53 +2.7%	N/A	-8.7%	£305.78M	£9.17B	0.00	6,692
ABDX Abingdon Health	N/A	GBX 11.24 +2.2%	N/A	+89.2%	£27.80M	£9.57M	N/A	84	Gap Up
GDR genedrive	N/A	GBX 1.28 -1.5%	N/A	+144.2%	£20.87M	£929K	N/A	43
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DXRX) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, ABDX, GDR, YGEN, and AGL

How does Diaceutics compare to Integrated Diagnostics?

Summary

How does Diaceutics compare to Abingdon Health?

Summary

How does Diaceutics compare to genedrive?

Summary

How does Diaceutics compare to Yourgene Health?

Summary

How does Diaceutics compare to ANGLE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, ABDX, GDR, YGEN, and AGL

How does Diaceutics compare to Integrated Diagnostics?

Which has preferable valuation & earnings, DXRX or IDHC?

Is DXRX or IDHC more profitable?

Do analysts prefer DXRX or IDHC?

Do institutionals and insiders believe in DXRX or IDHC?

Which has more volatility & risk, DXRX or IDHC?

Does the media refer more to DXRX or IDHC?

Summary

How does Diaceutics compare to Abingdon Health?

Do analysts recommend ABDX or DXRX?

Does the media prefer ABDX or DXRX?

Is ABDX or DXRX more profitable?

Do institutionals and insiders believe in ABDX or DXRX?

Which has preferable valuation and earnings, ABDX or DXRX?

Which has more volatility and risk, ABDX or DXRX?

Summary

How does Diaceutics compare to genedrive?

Is GDR or DXRX more profitable?

Do analysts rate GDR or DXRX?

Do institutionals & insiders believe in GDR or DXRX?

Which has stronger earnings and valuation, GDR or DXRX?

Does the media prefer GDR or DXRX?

Which has more volatility and risk, GDR or DXRX?

Summary

How does Diaceutics compare to Yourgene Health?

Which has preferable earnings and valuation, DXRX or YGEN?

Do institutionals and insiders hold more shares of DXRX or YGEN?

Do analysts rate DXRX or YGEN?

Does the media favor DXRX or YGEN?

Is DXRX or YGEN more profitable?

Which has more volatility & risk, DXRX or YGEN?

Summary

How does Diaceutics compare to ANGLE?

Is DXRX or AGL more profitable?

Which has stronger earnings & valuation, DXRX or AGL?

Which has more risk and volatility, DXRX or AGL?

Do analysts rate DXRX or AGL?

Do institutionals & insiders hold more shares of DXRX or AGL?

Does the media refer more to DXRX or AGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools